typical vs atypical antipsychotics
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive material from Katzung, Maudsley, and Goodman & Gilman. Let me compose the full response.
Typical vs. Atypical Antipsychotics
Background and Terminology
The original distinction between "typical" and "atypical" antipsychotics was based on the propensity to cause extrapyramidal side effects (EPS). Clozapine was the first drug recognized as "atypical" because it produced antipsychotic effects without causing EPS or catalepsy in animal models. Today, these two classes are more formally called first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) - though this terminology is convention rather than a rigorous scientific distinction, as noted in the Maudsley Prescribing Guidelines (15th ed).
1. Mechanisms of Action
Typical (FGAs) - Primary D2 Blockade
FGAs act primarily by blocking D2 dopamine receptors in the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways. This D2 blockade:
- Reduces positive symptoms (hallucinations, delusions) via mesolimbic D2 blockade
- Causes EPS (parkinsonism, akathisia, dystonia) via nigrostriatal D2 blockade
- Causes hyperprolactinaemia via tuberoinfundibular D2 blockade
- Has little effect on negative or cognitive symptoms (because these may require prefrontal dopamine activity, not suppression)
A neuroleptic is a subtype of antipsychotic drug that produces a high incidence of EPS at clinically effective doses, or catalepsy in laboratory animals. - Katzung's Basic and Clinical Pharmacology, 16th Ed.
Atypical (SGAs) - D2 + 5-HT2A Blockade (and More)
SGAs have broader receptor profiles. The key features:
- D2 + 5-HT2A inverse agonism: 5-HT2A blockade modulates dopamine release in the prefrontal cortex, reducing EPS liability while maintaining antipsychotic efficacy. This is the defining pharmacological feature of the main SGA class (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, lurasidone, etc.)
- 5-HT2C inverse agonism (clozapine, olanzapine, asenapine): contributes to weight gain and metabolic effects
- Dopamine partial agonism (aripiprazole, brexpiprazole, cariprazine): acts as a "dopamine stabilizer" - agonist when dopamine is low, antagonist when high
- D4 receptor affinity (clozapine, some others)
- α-adrenergic, histamine H1, muscarinic receptor blockade (varies by agent)
5-HT2A-receptor blockade is a key factor in the mechanism of action of the main class of second-generation antipsychotic drugs... These drugs are inverse agonists of the 5-HT2A receptor; they modulate the release of dopamine, norepinephrine, glutamate, GABA, and acetylcholine in the cortex, limbic region, and striatum. - Katzung's Basic and Clinical Pharmacology, 16th Ed.
2. Drug Examples
| Class | Drug | Chemical Class | Notable Features |
|---|---|---|---|
| FGA (Typical) | Chlorpromazine | Phenothiazine (aliphatic) | Low potency, high sedation, high hypotension |
| Fluphenazine | Phenothiazine (piperazine) | High potency, very high EPS | |
| Haloperidol | Butyrophenone | Very high potency, very high EPS, low sedation | |
| Thiothixene | Thioxanthene | High potency | |
| Perphenazine | Phenothiazine (piperazine) | Intermediate | |
| Trifluoperazine | Phenothiazine (piperazine) | High EPS liability | |
| SGA (Atypical) | Clozapine | Dibenzodiazepine | Prototype atypical; best for treatment-resistant; risk of agranulocytosis |
| Risperidone | Benzisoxazole | High D2/5-HT2A ratio; dose-dependent EPS | |
| Olanzapine | Thienobenzodiazepine | High metabolic risk; superior efficacy | |
| Quetiapine | Dibenzothiazepine | Very low EPS; useful for bipolar/depression | |
| Aripiprazole | Dihydrocarbostyril | D2 partial agonist; weight-neutral | |
| Ziprasidone | Benzisothiazolyl | Low metabolic risk; QTc prolongation | |
| Lurasidone | - | Low metabolic risk; good for bipolar depression | |
| Cariprazine | - | D3 preferring partial agonist; targets negative symptoms | |
| Asenapine | - | Sublingual; broad receptor profile |
3. D2/5-HT2A Ratio - The Key Differentiator
The D2/5-HT2A ratio explains much of the typical vs atypical distinction. From Katzung's comparison table:
| Drug | D2/5-HT2A Ratio | EPS Risk | Sedation | Hypotension |
|---|---|---|---|---|
| Chlorpromazine (FGA) | High | Medium | High | High |
| Fluphenazine (FGA) | High | High | Low | Very low |
| Haloperidol (FGA) | Medium | Very high | Low | Very low |
| Clozapine (SGA) | Very low | Very low | Low | Medium |
| Risperidone (SGA) | Very low | Low* | Low | Low |
| Olanzapine (SGA) | Low | Very low | Medium | Low |
| Quetiapine (SGA) | Low | Very low | Medium | Low-medium |
| Aripiprazole (SGA) | Medium | Very low | Very low | Low |
*Risperidone EPS is dose-dependent; at maximum doses it is "just about as 'typical' as a drug can be" - Maudsley Guidelines
4. Clinical Efficacy
Positive symptoms
Both FGAs and SGAs are effective for positive symptoms (hallucinations, delusions, disorganized thought). Head-to-head, the CATIE and CUtLASS trials found no convincing overall class advantage for SGAs over FGAs if EPS is controlled with careful dosing.
Negative symptoms
SGAs (particularly clozapine, amisulpride, cariprazine) have some advantage for negative symptoms, possibly because:
- 5-HT2A blockade enhances prefrontal dopamine activity
- FGAs can cause neuroleptic-induced dysphoria and pseudo-parkinsonism that mimic negative symptoms
- D3-preferring agents (cariprazine) may specifically target motivational negative symptoms
Treatment-resistant schizophrenia
Clozapine is the only drug proven effective in treatment-resistant cases, with response rates of 40-60% vs <5% for other agents. According to Goodman & Gilman's, olanzapine (7-9% response rate) is often used before clozapine given its more favorable monitoring burden.
Network meta-analysis ranking (2019, 32 antipsychotics):
- Amisulpride - best for positive symptoms
- Clozapine - best for negative symptoms and overall improvement
- Olanzapine and risperidone - highly ranked for positive symptoms
5. Side Effect Profiles
EPS - Higher with FGAs
| EPS Type | Onset | Mechanism | Treatment |
|---|---|---|---|
| Acute dystonia | Hours-days | D2 blockade in nigrostriatal | Anticholinergics (benztropine) |
| Akathisia | Days-weeks | D2/dopamine dysregulation | Propranolol, benzodiazepines |
| Parkinsonism | Weeks | Nigrostriatal D2 blockade | Reduce dose, anticholinergics |
| Tardive dyskinesia | Months-years | Dopamine receptor supersensitivity | Valbenazine, clonazepam; prevention is key |
Tardive dyskinesia (TD) risk: estimated at ~7.2% with chronic SGA use in FGA-naive patients - still a real risk, not zero. FGAs carry substantially higher TD risk.
Metabolic Side Effects - Higher with SGAs (especially clozapine, olanzapine, quetiapine)
| Effect | High Risk Drugs | Low Risk Drugs |
|---|---|---|
| Weight gain | Clozapine, olanzapine | Aripiprazole, ziprasidone, lurasidone |
| Dyslipidemia (↑TG) | Clozapine, olanzapine | Aripiprazole, ziprasidone |
| Hyperglycemia/T2DM | Clozapine, olanzapine, quetiapine | Aripiprazole, lurasidone |
The risk of developing diabetes with atypical antipsychotic agents appears to be higher than with typical antipsychotic agents. - Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Hyperprolactinaemia
- FGAs: all cause significant hyperprolactinaemia (via tuberoinfundibular D2 blockade)
- SGAs: risperidone and paliperidone cause more prolactin elevation than most FGAs; clozapine and quetiapine cause minimal prolactin rise; aripiprazole can actually lower prolactin
Other Key Adverse Effects
| Effect | Most Associated Drugs |
|---|---|
| Agranulocytosis | Clozapine (~1%; requires mandatory REMS monitoring), rarely chlorpromazine |
| Sedation | Chlorpromazine, clozapine, quetiapine (H1 antagonism) |
| QTc prolongation | Ziprasidone, thioridazine, haloperidol IV |
| Anticholinergic (dry mouth, urinary retention, constipation) | Clozapine, chlorpromazine, olanzapine |
| Postural hypotension | Chlorpromazine, clozapine (α1 blockade) |
| Neuroleptic Malignant Syndrome (NMS) | Any antipsychotic; higher risk with high-potency FGAs |
| Seizures | Clozapine (dose-dependent) |
| Myocarditis/cardiomyopathy | Clozapine |
6. Summary Comparison Table
| Feature | Typical (FGA) | Atypical (SGA) |
|---|---|---|
| Primary mechanism | D2 blockade | D2 + 5-HT2A blockade (± others) |
| Positive symptoms | Effective | Effective |
| Negative symptoms | Minimal benefit | Some benefit (varies by agent) |
| Cognitive symptoms | Minimal | Modest improvement (some agents) |
| EPS risk | High | Low (dose-dependent for some) |
| Tardive dyskinesia | High (chronic use) | Lower, but not zero (~7%) |
| Metabolic effects | Low | Variable; high for clozapine/olanzapine |
| Prolactin elevation | All FGAs | Varies; risperidone > most FGAs |
| Agranulocytosis | Rare | Clozapine ~1% |
| Cost | Low | Generally higher (many now generic) |
| LAI availability | Yes (fluphenazine, haloperidol decanoate) | Yes (aripiprazole, paliperidone, risperidone LAIs) |
7. Clinical Decision-Making
Per the Maudsley Prescribing Guidelines (15th ed.), the typical/atypical classification is now considered more a convention than a scientific framework. Individual drug properties matter more than class when choosing:
- First episode psychosis: most guidelines recommend an SGA (lower EPS) - olanzapine or amisulpride show slight efficacy advantages
- Treatment-resistant (failed 2+ antipsychotics): clozapine is the evidence-based choice
- Metabolic concerns: aripiprazole, lurasidone, ziprasidone (weight-neutral or minimal gain)
- Non-adherence: long-acting injectable (LAI) preparations of both FGAs and SGAs improve relapse rates
- Bipolar disorder: SGAs (olanzapine, risperidone, quetiapine, aripiprazole, cariprazine) are first-line for acute mania; quetiapine and lurasidone for bipolar depression
The real practical distinction is: with SGAs, an effective dose can usually be chosen that avoids EPS; with FGAs (especially high-potency ones like haloperidol), the therapeutic window overlaps heavily with the EPS-producing window.
Sources:
- Katzung's Basic and Clinical Pharmacology, 16th Edition - Antipsychotic Agents chapter
- The Maudsley Prescribing Guidelines in Psychiatry, 15th Edition - Classification, efficacy, and adverse effects
- Goodman & Gilman's The Pharmacological Basis of Therapeutics - Antipsychotic Agents, treatment selection
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Metabolic effects, dopamine receptors
This is a shared conversation. Sign in to Orris to start your own chat.